Cells for Cells S.A. is a Chilean-based biotech company dedicated to the research, development and commercialization of cell therapies and tissue-engineered revolutionary solutions. The company counts with a broad portfolio of more than 10 technologies including Cellistem®OA, a clinical trial-supported cell therapy for the treatment of knee osteoarthritis, Inkure®, a bioink for the treatment of focal chondral lesions, Oxium®Exo, a culture media for the production of exosomes, and Veintis™, a bioinspired tissue-engineered vascular graft for vascular bypass applications, among others. Cells for Cells S.A. (a.k.a. C4C) is a spin off from Universidad de los Andes, Chile, and was founded in 2010.